MGI Tech Co., Ltd. and JCBio Co., Ltd. have signed a Memorandum of Understanding (MoU) to launch the DCS Lab Project.
The initiative aims to accelerate multi-omics research, novel sequencing applications, precision medicine, clinical translation, and AI-driven data insights in South Korea. By combining MGI’s omics technologies with JCBio’s local expertise, the partnership aims to empower researchers and clinicians while strengthening South Korea’s role as a regional leader in genomics and biotechnology.
In an era where multi-omics research is reshaping healthcare, the collaboration between MGI Tech and JCBio strengthens South Korea’s genomics ecosystem. By combining MGI’s proprietary short-read and long-read sequencing technologies, the initiative equips JCBio’s laboratories with end-to-end multi-omics capabilities, enabling researchers to tackle complex biological challenges with greater precision and efficiency.
Under the DCS Lab Project, JCBio is empowered to implement innovative sequencing strategies, advance integrated multi-omics analyses, explore novel sequencing applications, accelerate precision medicine, clinical translation, and AI-driven data insights—positioning the laboratory as a local hub for genomic research and multi-omics innovation.
Launched in 2023, MGI’s DCS Lab Initiative was established to empower international laboratories with sequencing solutions. Named after MGI’s three core technologies—DNA genomics, Cell omics, and Spatial omics—the DCS Lab initiative is the company’s first global programme targeting international laboratories with a focus on frontier science. It represents MGI’s capability within the industry to provide end-to-end products for applications ranging from DNA genomics to cell omics and spatial omics.
The initiative has already enabled pioneering research worldwide. At MGI’s Customer Experience Centre (CEC) in Australia, technologies such as DNBelab-C4 for single-cell omics and STOmics Stereo-seq for spatial transcriptomics have driven breakthroughs in cancer, medicine, and agriculture. Building on this success, MGI is now extending the programme to South Korea in collaboration with JCBio—reinforcing the nation’s role as a key hub in Asia’s rapidly growing biotech ecosystem.
“We are excited to partner with JCBio, an organisation that shares our commitment to scientific excellence and innovation,” said Roy Tan, director of MGI Northeast Asia.
“With the DCS Lab Project, we are not only deploying sequencing platforms but establishing a hub for multi-omics discovery that equips South Korea’s research community with the tools to drive frontier science and improve human health.”
“This partnership with MGI is a game-changer for South Korea’s research community,” said JaeChan Yoo, CEO of JCBio.
“By integrating long- and short-read sequencing technologies, the DCS Lab enables researchers to tackle complex biological questions and accelerate breakthroughs in precision medicine and multi-omics research. Together, we are supporting South Korea’s growing role in global genomics research.”
Jim Cornall is editor of Deeptech Digest and publisher at Ayr Coastal Media. He is an award-winning writer, editor, photographer, broadcaster, designer and author. Contact Jim here.
